Streetbeat News

ELVN

Enliven Therapeutics, Inc.

https://www.enliventherapeutics.com

Industry

Biotechnology

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Open

20.57

Mkt cap

994M

Volume

238K

High

21.05

P/E Ratio

-10.73

52-wk high

30.03

Low

20.27

Div yield

N/A

52-wk low

15.96

Enliven Therapeutics (NASDAQ:ELVN) reported a Q2 EPS of $(0.41), beating the analyst consensus estimate of $(0.55) by 25.45%. This result is unchanged from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 8:36 pm

Baird analyst Colleen Kusy has initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an Outperform rating and set a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 9:13 am

Enliven Therapeutics reported its Q1 2024 earnings with an adjusted EPS of $(0.54), surpassing the consensus estimate of $(0.57) by 5.26%.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:32 pm

Enliven Therapeutics Inc (NASDAQ:ELVN) released Phase 1 clinical trial data for ELVN-001, a kinase inhibitor targeting BCR-ABL gene fusion in CML patients. The trial showed a 44% major molecular response rate at 12 weeks, with no significant toxicities, supporting once-daily dosing. ELVN shares surged 23.60% to $24.50.

Portfolio Pulse from Vandana Singh

April 11, 2024 | 5:44 pm

Fastenal Company's shares dropped by around 7% due to disappointing Q1 FY24 financial results, with sales and EPS missing consensus estimates. Other stocks experienced significant movements, with Rallybio Corporation, Rent the Runway, and Eliem Therapeutics among the top gainers, while Aptevo Therapeutics, Enlivex Therapeutics, and AVITA Medical led the losers.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 5:33 pm

Enliven Therapeutics shares surged following the announcement of positive proof of concept data from a Phase 1 clinical trial for ELVN-001, aimed at treating chronic myeloid leukemia.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 2:13 pm

Enliven Therapeutics announced positive Phase 1 trial data for ELVN-001, causing a 26% surge in its stock. Alpine Immune Sciences saw a 36.6% jump after an acquisition agreement with Vertex. Janux Therapeutics' shares rose 16.8% amid sale considerations. Other notable movers include Rallybio Corporation with an 89.6% gain following a collaboration with Johnson & Johnson, and AnaptysBio, which rose 11.4% after an Overweight rating from Wells Fargo.

Portfolio Pulse from Avi Kapoor

April 11, 2024 | 2:01 pm

Mizuho Securities initiated coverage on Enliven Therapeutics Inc (NASDAQ:ELVN), a precision oncology company, with a Buy rating and a price target of $34. ELVN's lead product, ELVN-001, targets Chronic myelogenous leukemia (CML) and is under development. The global CML market is valued at $13-$14 billion, with ELVN trading at conservative levels compared to its potential. Novartis AG (NYSE:NVS) was mentioned as having developed the first TKI for CML. ELVN shares rose 3.72% to $18.98.

Portfolio Pulse from Vandana Singh

April 09, 2024 | 6:26 pm

Mizuho analyst Salim Syed initiates coverage on Enliven Therapeutics (ELVN) with a Buy rating and a price target of $34.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 12:11 pm

Enliven Therapeutics, Inc. (NASDAQ:ELVN) announced a virtual event on April 11, 2024, to share initial proof of concept data for ELVN-001, a kinase inhibitor targeting CML. The event will feature discussions with leading CML experts and Enliven's management, focusing on ELVN-001's Phase 1a data and its potential impact on CML treatment.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.